Fibroblast Growth Factor Receptors (FGFRs) are a family of FGF-binding transmembrane receptors involved in regulating cell growth and proliferation, angiogenesis, and numerous developmental processes. They are highly conserved, consisting of three extracellular immunoglobulin-type domains, IgI, IgII, and IgIII, which enable ligand binding, a transmembrane domain, and an intracellular tyrosine kinase domain which exerts its downstream signaling effects. The signaling pathway activated by FGFR/FGF has been implicated in several cancers; consequently, FGFR inhibitors are being investigated as potential therapeutic agents in many cancer studies.
The test classifies and predicts COVID-19 disease severity, based on host response to COVID-19.
The test predicts whether COVID-19 patients:
are likely to develop severe disease (WHO 3 vs WHO 4-7);
will need invasive ventilation;
are likely to survive if they have severe disease.
The purpose of the biomarker test is to demonstrate treatment efficacy, elucidate the MoA of COVID-19 therapeutics in development and to provide a readout of what the disease would have looked like without treatment.